{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:15:14Z","timestamp":1791357314832,"version":"4.3.1"},"reference-count":48,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T00:00:00Z","timestamp":1518912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Tardive dyskinesia is a potentially irreversible, debilitating, hyperkinetic movement disorder that can result from dopamine receptor antagonists. Prompt recognition and resolution of symptoms are instrumental in preventing disease irreversibility, though current treatment options have fallen short of robust, effective, and long-term symptom control. In April 2017, the Food and Drug Administration (FDA) approved 2 new vesicular monoamine transporter 2 (VMAT2) inhibitors, deutetrabenazine and valbenazine, for chorea related to Huntington\u2019s disease and tardive dyskinesia, respectively. These agents were pharmacologically modified from tetrabenazine, a VMAT2 inhibitor used off-label in the treatment of tardive dyskinesia. Despite FDA-labeled indications of deutetrabenazine and valbenazine, each agent was explored as a treatment option for those with tardive dyskinesia. In this study, the pharmacologic modifications of the 2 new VMAT2 inhibitors are described, with detailed explanation as to how these may impact clinical practice. The associated case series, observational studies, and clinical trials exploring their use in the treatment of tardive dyskinesia are reported with expert opinion on practice implication.<\/jats:p>","DOI":"10.1177\/0897190018756512","type":"journal-article","created":{"date-parts":[[2018,2,18]],"date-time":"2018-02-18T23:31:33Z","timestamp":1518996693000},"page":"450-457","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["VMAT2 Inhibitors for Tardive Dyskinesia\u2014Practice Implications"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-7005","authenticated-orcid":false,"given":"Alyssa M.","family":"Peckham","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Midwestern University College of Pharmacy-Glendale, Glendale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Nicewonder","sequence":"additional","affiliation":[{"name":"Midwestern University College of Pharmacy-Glendale, Glendale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,2,18]]},"reference":[{"key":"bibr1-0897190018756512","volume":"3","author":"Waln O","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"bibr2-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-005-0016-0"},{"key":"bibr3-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12270"},{"issue":"6","key":"bibr4-0897190018756512","first-page":"677","volume":"20","author":"Othman Z","year":"2013","journal-title":"Int Med J"},{"key":"bibr5-0897190018756512","unstructured":"Stahl S. M. Essential Psychopharmacology Online. 2008. https:\/\/stahlonline.cambridge.org\/essential_4th_chapter.jsf?page=chapter5_introduction.htm&name=Chapter 5&title=Antipsychotic agents#c02598-5-16.Accessed October 24, 2017."},{"key":"bibr6-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505000907"},{"key":"bibr7-0897190018756512","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2016.00207"},{"key":"bibr8-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.12.019"},{"key":"bibr9-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080478"},{"key":"bibr10-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.239160"},{"key":"bibr11-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31829d86b6"},{"key":"bibr12-0897190018756512","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Austedo NDA 208082 approval letter, April 3, 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/208082Orig1s000ltr.pdf. Accessed October 24, 2017."},{"key":"bibr13-0897190018756512","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Ingrezza NDA 209241 approval letter, April 11, 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/209241Orig1s000ltr.pdf. Accessed October 24, 2017."},{"issue":"12","key":"bibr14-0897190018756512","first-page":"690","volume":"33","author":"Yero T","year":"2008","journal-title":"P T"},{"key":"bibr15-0897190018756512","unstructured":"Product information. Xenazine (tetrabenazine). Deerfield, IL: Ovation Pharmaceuticals; Inc.; 2008."},{"key":"bibr16-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12964"},{"key":"bibr17-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410170217"},{"key":"bibr18-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318290cd41"},{"key":"bibr19-0897190018756512","doi-asserted-by":"publisher","DOI":"10.2165\/11208330-000000000-00000"},{"key":"bibr20-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.12.1283"},{"issue":"4","key":"bibr21-0897190018756512","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","volume":"130","author":"Kazamatsuri H","year":"1973","journal-title":"Am J Psychiatry"},{"key":"bibr22-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.8.1051"},{"key":"bibr23-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1177\/070674378803300104"},{"key":"bibr24-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.3.391"},{"key":"bibr25-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.2.358"},{"key":"bibr26-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.8.1279"},{"key":"bibr27-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000136892.24629.96"},{"key":"bibr28-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21222"},{"key":"bibr29-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616677004"},{"key":"bibr30-0897190018756512","unstructured":"Product information. Austedo (deutetrabenazine). North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2017."},{"key":"bibr31-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"bibr32-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-017-0051-5"},{"key":"bibr33-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003960"},{"key":"bibr34-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30236-5"},{"key":"bibr35-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1029573"},{"key":"bibr36-0897190018756512","unstructured":"Product information. Ingrezza (valbenazine). San Diego, CA: Neurocrine Biosciences, Inc. 2017."},{"key":"bibr37-0897190018756512","unstructured":"Neurocrine Biosciences. Neurocrine announces phase IIb results of VMAT2 inhibitor NBI-98854 for treatment of tardive dyskinesia [media release]. 2013. http:\/\/www.neurocrine.com\/. Accessed October 24, 2017."},{"key":"bibr38-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26330"},{"key":"bibr39-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16091037"},{"issue":"16","key":"bibr40-0897190018756512","volume":"88","author":"Factor S","year":"2017","journal-title":"Neurology"},{"key":"bibr41-0897190018756512","unstructured":"Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia (Kinect 4). 2017. http:\/\/clinicaltrials.gov\/ct2 (Identification No. NCT02405091). Accessed October 24, 2017."},{"key":"bibr42-0897190018756512","first-page":"c1974","volume-title":"Truven Health Analytics","author":"Ingrezza","year":"2017"},{"key":"bibr43-0897190018756512","first-page":"c1974","volume-title":"Truven Health Analytics","author":"Austedo","year":"2017"},{"key":"bibr44-0897190018756512","first-page":"c1974","volume-title":"Truven Health Analytics","author":"Tetrabenazine","year":"2017"},{"key":"bibr45-0897190018756512","unstructured":"Obamacare Facts. How Does Health Insurance Work? https:\/\/obamacarefacts.com\/health-insurance\/how-does-health-insurance-work\/. Accessed October 24, 2017."},{"key":"bibr46-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.183.3.197"},{"key":"bibr47-0897190018756512","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1386556"},{"key":"bibr48-0897190018756512","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2017-0065"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190018756512","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190018756512","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190018756512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:34:52Z","timestamp":1777509292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190018756512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,18]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1177\/0897190018756512"],"URL":"https:\/\/doi.org\/10.1177\/0897190018756512","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,18]]}}}